Cell Therapy and Bioanalysis: Monitoring Patient Safety in CAR-T Trials

A Different Kind of Drug

CAR-T cell therapies are not small molecules. They are not even biologics in the conventional sense. They are living, replicating therapeutic agents: a patient’s own T cells, extracted, genetically modified to express a chimeric antigen receptor, expanded ex vivo, and reinfused to hunt and destroy tumour cells.

That extraordinary mechanism of action creates an equally extraordinary monitoring challenge. You cannot measure a CAR-T therapy with a plasma concentration assay. The drug proliferates, differentiates, and persists for months or years after a single dose. Monitoring it requires an entirely different bioanalytical toolkit.

What You Are Actually Measuring

CAR-T Cell Persistence

The key pharmacokinetic question for a CAR-T product is not concentration but persistence: are the CAR-T cells still present, and in what numbers? Quantitative PCR targeting the transgene sequence is the standard method for measuring CAR-T cell levels in peripheral blood over time. Flow cytometry using CAR-specific antibodies or antigen-binding probes provides complementary phenotypic data on the composition and activation state of the persisting cells.

Cytokine Release Monitoring

CAR-T therapies can trigger cytokine release syndrome (CRS), a potentially life-threatening inflammatory response caused by the rapid activation of T cells and bystander immune cells. Monitoring key cytokines including IL-6, IFN-gamma, and ferritin in plasma allows clinical teams to detect CRS early and intervene before it progresses to severe grades. The bioanalytical assay must be sensitive enough to detect early cytokine rises against a variable baseline.

Neurotoxicity Markers

Immune effector cell-associated neurotoxicity syndrome (ICANS) is the other major safety concern in CAR-T therapy. CSF biomarkers including GFAP and neurofilament light chain are being evaluated as early indicators of neurological inflammation. Reliable quantification of these markers in CSF, a matrix with very different properties from plasma, requires assay-specific validation.

The Bioanalytical Package for a CAR-T IND

Assay	Matrix	Method	Regulatory Purpose
CAR-T cell quantification	Peripheral blood	ddPCR or qPCR targeting transgene; flow cytometry	PK characterisation; persistence data for safety assessment
Cytokine panel (IL-6, IFN-gamma, TNF-alpha, IL-2)	Plasma/serum	Multiplex MSD or single-plex ELISA	CRS monitoring; pharmacodynamic response
Anti-CAR antibody (ACA) detection	Serum	Bridging LBA; tiered immunogenicity strategy	Immunogenicity assessment; impact on cell persistence
CAR-T phenotyping (CD4/CD8, memory, exhaustion)	Peripheral blood	Multi-parametric flow cytometry	Pharmacodynamic characterisation; mechanism of action evidence
Tumour burden assessment	Blood (liquid biopsy) or tissue	ctDNA by NGS; tumour marker by validated immunoassay	Efficacy endpoint; correlation with CAR-T expansion
Safety biomarkers (GFAP, NfL for ICANS)	CSF / plasma	Digital ELISA (Simoa) or MSD	Neurotoxicity monitoring; exploratory safety biomarker

The Validation Challenge: No Stable Reference Standard

One of the most practically difficult aspects of CAR-T bioanalysis is that the analyte itself, the genetically modified T cell, is not a stable reference standard. Cell-based assays cannot be validated in the same way as small molecule or protein assays. The cell population changes phenotype over time in culture, and the reference material used for one validation run may not be biologically equivalent to the material used for the next.

Regulatory guidance from both the FDA and the EMA has evolved to acknowledge this challenge. A fit-for-purpose approach is accepted for many CAR-T bioanalytical assays, where the validation scope is defined by the intended use of the data and the decisions it will support, rather than by the full panel of ICH M10 parameters applicable to a conventional drug concentration assay.

Ardena’s Cell Therapy Bioanalysis at Assen

Ardena’s bioanalytical team at Assen supports cell therapy programmes with ddPCR-based transgene quantification, multi-parametric flow cytometry for CAR-T phenotyping, multiplex cytokine assays, and immunogenicity testing for anti-CAR antibodies. The team takes a programme-specific approach to assay development and validation, working with sponsors to define the right level of validation rigour for each assay based on its role in the clinical decision-making framework.

The Future of mRNA Delivery: Beyond COVID-19 Vaccines

A Platform Proven at Unprecedented Scale

The COVID-19 pandemic accelerated the clinical and regulatory validation of mRNA LNP technology at a pace that would otherwise have taken a decade. Within two years of the initial sequencing of the SARS-CoV-2 spike protein, billions of doses of mRNA vaccine had been manufactured, distributed globally, administered under emergency authorisation, and then fully approved by the FDA and EMA. The safety, immunogenicity, and manufacturing scalability of the mRNA LNP platform were demonstrated at a scale that no preclinical model could have predicted.

The scientific and industrial community that built the COVID-19 vaccine supply chain did not then stand still. The formulation scientists, manufacturing engineers, regulatory professionals, and clinical researchers who learned their trade on vaccine programmes are now applying the same platform to a new generation of therapeutic applications, each of which presents its own formulation challenges and clinical expectations.

Personalised Cancer Vaccines: mRNA as Precision Medicine

The most scientifically compelling near-term application of therapeutic mRNA beyond infectious disease is personalised cancer vaccination. Tumour cells accumulate somatic mutations that produce altered proteins called neoantigens, which are not present in normal tissue and are therefore visible to the immune system as foreign. A personalised cancer vaccine encodes the patient’s own tumour neoantigens in an mRNA construct, delivers it via LNP to antigen-presenting cells, and stimulates a T cell response targeted specifically at the tumour.

The clinical results from early trials of personalised mRNA cancer vaccines, including data from Moderna and Merck’s mRNA-4157/V940 programme in melanoma, have shown meaningful improvements in recurrence-free survival in combination with checkpoint inhibitor therapy. BioNTech’s BNT111 programme for melanoma and several other solid tumour programmes are advancing through Phase II, establishing the clinical evidence base for what could become a standard of care in tumour-specific adjuvant therapy.

Rare Genetic Diseases: Protein Replacement by mRNA

For rare genetic diseases caused by loss-of-function mutations that result in absent or non-functional proteins, mRNA therapeutics offer a route to protein replacement that is fundamentally different from enzyme replacement therapy (ERT) or gene therapy. Rather than administering the protein directly (ERT) or permanently correcting the gene (gene therapy), mRNA therapy temporarily restores protein expression by delivering the instructions for the normal protein to the patient’s own cells.

The transient nature of mRNA expression, typically lasting days to weeks depending on the mRNA design and the tissue target, is both a limitation and a safety feature. The treatment must be repeated at regular intervals, but the absence of permanent genomic modification eliminates the risk of insertional mutagenesis associated with viral gene therapy vectors. For diseases like methylmalonic acidemia, propionic acidemia, and other inborn errors of metabolism affecting the liver, mRNA LNP therapy delivered intravenously to hepatocytes is an active area of clinical investigation.

The Formulation Challenges That Remain Unsolved

Challenge	Clinical Implication	Active Research Direction
Extra-hepatic delivery	Most LNP platforms accumulate in the liver after IV administration; reaching lung, muscle, or tumour tissue requires active targeting or alternative routes	Selective organ targeting (SORT) lipids; receptor-targeted LNPs; inhaled LNP delivery for respiratory targets
Repeated dosing immunogenicity	PEG-specific IgM responses can cause accelerated blood clearance after repeat doses; some ionisable lipids generate innate immune responses	PEG-alternatives (PEGylation-free LNPs); optimised immunisation schedules; stealth LNP designs
mRNA half-life in vivo	Unmodified mRNA is rapidly degraded; modified nucleosides improve stability but add manufacturing complexity	Circular mRNA; self-amplifying mRNA for lower doses; codon and UTR optimisation for enhanced expression
Cold chain dependency	Current approved mRNA products require storage at minus 20 or minus 80 degrees C, limiting access in resource-limited settings	Thermostable formulations; lyophilised mRNA LNP products; room-temperature stable excipient systems
Manufacturing cost at personalised scale	Personalised cancer vaccines require individual mRNA synthesis per patient; current GMP cost is high	Automated mRNA synthesis platforms; modular GMP; point-of-care manufacturing concepts

What the Expanding mRNA Pipeline Demands from CDMOs

The breadth of the mRNA therapeutic pipeline, from infectious disease vaccines to oncology, rare disease, and cardiac applications, creates a formulation and manufacturing demand that is qualitatively different from the vaccine manufacturing experience. Cancer vaccine programmes require patient-specific mRNA synthesis and formulation under GMP conditions. Rare disease programmes require precision dosing, specialised patient populations, and regulatory packages adapted to small-batch GMP. Cardiac and pulmonary programmes may require inhaled or locally administered formulations that are outside the IV delivery paradigm of the COVID-19 vaccines.

CDMOs that can support this breadth of application need more than a microfluidics machine and a vial filler. They need formulation scientists who understand the relationship between LNP composition and delivery to specific tissue targets, analytical teams capable of characterising mRNA integrity and potency in complex formulation environments, and regulatory expertise in the evolving framework for mRNA therapeutics beyond the emergency authorisation pathway.

Ardena’s Role in the mRNA Therapeutic Pipeline

Ardena’s nanomedicine facility at Oss is positioned to support mRNA therapeutic development beyond the vaccine applications that established the platform. The formulation team has expertise in ionisable lipid-based LNP systems, and the analytical team at Oss and Assen provides the mRNA integrity, potency, and physicochemical characterisation capabilities needed for regulatory-grade data packages across vaccine and therapeutic applications.

LNP vs. Polymeric Nanoparticles: Choosing the Right Delivery Vehicle

Two Mature Platforms, Two Different Profiles

Lipid nanoparticles and biodegradable polymeric nanoparticles are both well-established pharmaceutical delivery platforms with approved products and substantial clinical track records. LNPs are the platform behind the COVID-19 mRNA vaccines, liposomal doxorubicin, and a growing range of nucleic acid therapeutics. Polymeric nanoparticles, particularly those based on PLGA and PLA, have been approved in long-acting injectable formulations including the goserelin depot (Zoladex) and have a strong development pipeline across oncology, neurology, and infectious disease.

Choosing between them is not always straightforward. Both can encapsulate small molecule APIs and both can be engineered for sustained release. The decision depends on the physicochemical properties of the molecule, the intended route of administration, the target release profile, the regulatory pathway, and the manufacturing infrastructure available at the development partner.

Head-to-Head Platform Comparison

Factor	Lipid Nanoparticles (LNP)	PLGA Polymeric Nanoparticles
Primary payload types	Nucleic acids (mRNA, siRNA, DNA); small molecules; peptides	Small molecules; peptides; proteins; hydrophilic and hydrophobic drugs
Release profile	Typically rapid; burst release unless specifically engineered for sustained delivery	Tunable sustained release from days to months based on polymer MW and composition
Biodegradability	Lipid components metabolised via natural lipid pathways	Hydrolytic degradation to lactic acid and glycolic acid; natural metabolites
Stability in circulation	Ionisable LNPs designed for stability in blood; PEGylation extends circulation half-life	PLGA NPs stable in circulation; surface properties affect protein adsorption and clearance
Administration routes	IV (oncology, nucleic acid); IM (vaccines); potentially inhaled	IM/SC depot (sustained release); IV; potentially oral
Manufacturing technology	Microfluidics; extrusion; established at GMP scale	Nanoprecipitation; emulsion-solvent evaporation; established at GMP scale
Regulatory precedent	Strong: Onpattro (siRNA LNP), mRNA vaccines, Doxil (liposome)	Strong: Lupron Depot, Zoladex (PLGA microspheres); growing body for nanoparticles
Best suited for	Nucleic acid delivery; rapid onset injectables; vaccines	Sustained release injectables; small molecule payloads; depot formulations

When LNPs Win

If your payload is a nucleic acid, the case for an LNP platform is essentially settled. The ionisable lipid system is specifically designed to encapsulate negatively charged nucleic acids at high efficiency, protect them from enzymatic degradation in the extracellular environment, and facilitate endosomal escape after cellular uptake. No polymer nanoparticle system has demonstrated equivalent nucleic acid delivery efficiency in systemic applications.

For small molecule payloads that need rapid release, such as anti-cancer agents that need to achieve high intracellular concentrations quickly after uptake, LNPs also have an advantage over slowly degrading PLGA systems. The clinical success of liposomal doxorubicin (Doxil) in extending the circulation half-life of the drug while reducing cardiotoxicity relative to free doxorubicin is a demonstration of this principle.

When Polymeric Nanoparticles Win

For programmes where the clinical objective requires drug release over days, weeks, or months from a single injection, PLGA-based systems have an advantage that is difficult to replicate with LNPs. The tunable degradation rate of PLGA, combined with well-characterised manufacturing processes for microspheres and nanoparticles, makes it the platform of choice for depot injectable programmes where patient compliance with daily dosing is a limiting factor.

For small molecule payloads where stability in an aqueous lipid environment is a concern, encapsulation within a solid polymer matrix can offer better protection than an LNP core. Hydrophilic molecules that do not partition efficiently into the lipid phase of an LNP also tend to be better suited to polymer matrix systems that can encapsulate them within an aqueous core or adsorb them to a polymer surface.

Ardena’s Dual Platform Capability at Oss

Ardena’s nanomedicine team at Oss has development and GMP manufacturing capabilities for both LNP and polymeric nanoparticle platforms. The team can advise on platform selection based on the molecule’s physicochemical profile and the programme’s clinical and regulatory objectives, and can design feasibility studies that compare platform options before a full development programme is committed to a single technology.

Scaling LNP Production: From Lab Bench to GMP Manufacturing

The Scale-Up Challenge Specific to LNPs

Scale-up is a challenge in pharmaceutical manufacturing generally, but it is a particularly acute challenge for lipid nanoparticle products. For a conventional tablet, scaling from a 1 kilogram development batch to a 100 kilogram GMP batch involves larger equipment with similar operating principles, and the scale-up relationships, though not always straightforward, are well understood from decades of industrial experience.

For LNPs manufactured by microfluidics, the situation is different. Microfluidic devices work by mixing two streams, an organic phase containing the lipids and an aqueous phase containing the nucleic acid payload, at controlled flow rates and flow rate ratios in a microchannel. The particle size and size distribution depend critically on the mixing characteristics within the channel, which are determined by the fluid dynamics at the specific flow rates and channel geometry used. Changing the scale of the process means changing the equipment, which changes the fluid dynamics, which can change the product.

Microfluidics Scale-Up: The Key Variables

Scale Variable	Effect on LNP Properties	Scale-Up Strategy
Total flow rate	Higher flow rates increase mixing efficiency but can increase shear stress on particles	Maintain flow rate ratio (FRR) constant; scale total flow rate with batch size using parallel channels or larger devices
Flow rate ratio (FRR)	Primary determinant of initial particle size: higher aqueous:organic ratio gives smaller particles	Keep FRR constant across scales; validate that target particle size is achieved at each scale
Mixing geometry	Different microfluidic chips produce different mixing regimes; particle size can differ between chip types	Qualify each chip type at target scale; use manufacturer scale-up data as starting point
Lipid concentration in organic phase	Higher lipid concentration can increase particle size and polydispersity	Optimise lipid concentration at development scale; confirm at GMP scale before batch manufacture
mRNA concentration in aqueous phase	Affects N:P ratio and encapsulation efficiency	Keep N:P ratio constant; calculate mRNA concentration to maintain N:P at target
Post-mixing dilution and buffer exchange	Buffer exchange by tangential flow filtration (TFF) affects particle stability and formulation pH	Validate TFF parameters (transmembrane pressure, cross-flow rate) at each scale; monitor particle size through TFF

Tangential Flow Filtration: The Step That Trips Up Scale-Up

After LNP formation by microfluidics, the product is in an organic solvent-containing medium that needs to be replaced with the final formulation buffer, and the product needs to be concentrated to the target dose concentration. Tangential flow filtration (TFF) is the standard approach for both buffer exchange and concentration of LNP products.

TFF passes the LNP suspension across a semipermeable membrane under a controlled transmembrane pressure, with smaller molecules (solvents, unencapsulated nucleic acid, buffer components) passing through the membrane while the LNPs are retained and concentrated. The process parameters, transmembrane pressure, cross-flow velocity, number of diafiltration volumes, and membrane molecular weight cut-off, all affect both the efficiency of the process and the quality of the retained LNP product.

At development scale, TFF is typically conducted in small-volume hollow fibre cartridges. At GMP manufacturing scale, larger cartridges or multiple units in parallel are used. The transition can introduce unexpected changes in shear stress on the particles and in the effective membrane area available for the batch size, affecting product quality and yield. TFF parameters must be re-optimised and validated at each manufacturing scale.

Process Analytical Technology in LNP Scale-Up

Process analytical technology (PAT) tools are particularly valuable in LNP manufacturing scale-up because they allow critical quality attributes to be monitored in real time rather than measured only at batch release. In-line or at-line dynamic light scattering can detect particle size changes during the mixing or TFF steps before they result in an out-of-specification batch. In-line fluorescence monitoring using intercalating dyes can provide a real-time indicator of encapsulation efficiency during the formulation process.

The FDA has actively encouraged PAT adoption in pharmaceutical manufacturing through its process validation guidance, and for complex products like LNPs where batch failure is expensive and the consequences of size distribution changes on clinical performance are significant, the investment in PAT capability during scale-up is well justified.

Ardena’s LNP Scale-Up Capabilities at Oss

Ardena’s GMP nanomedicine manufacturing facility in Oss operates microfluidics equipment capable of producing LNP batches at both development and GMP clinical scale. The site has TFF capability for buffer exchange and concentration, with process development experience in optimising TFF parameters for LNP products. Scale-up from development batches to GMP clinical batches is managed within the same facility, with the same formulation team involved at each scale.

Spray Drying for Bioavailability: Overcoming BCS Class II Challenges

Why Spray Drying Has a Thirty-Year Track Record in Pharma

Spray drying is not a new technology. It has been used in the food industry for over a century and in pharmaceutical manufacturing since the 1980s. What makes it particularly relevant to modern drug development is the growth of the BCS Class II molecule pipeline: drugs that are highly permeable but poorly soluble, and for which dissolution in the gastrointestinal fluid is the rate-limiting step in absorption.

For these molecules, converting the crystalline API into an amorphous form and dispersing it within a polymer matrix by spray drying provides a dissolution advantage that can increase oral bioavailability by two to tenfold or more, depending on the molecule and the formulation. The first spray-dried amorphous dispersion approved for a major indication was the HIV protease inhibitor ritonavir in Norvir capsules in the late 1990s. Since then, the technology has been applied to dozens of approved products across oncology, virology, and other therapeutic areas.

The Spray Drying Process: What Happens Inside the Dryer

In a spray drying process for amorphous solid dispersion (ASD) manufacture, the API and polymer are co-dissolved in an organic solvent, most commonly acetone, ethanol, methanol, dichloromethane, or a mixture of these. The solution is pumped to an atomiser, typically a two-fluid nozzle or a rotary atomiser, which breaks the solution into fine droplets that are sprayed into a heated drying chamber. Hot nitrogen or air flows through the chamber, evaporating the solvent from the droplets within milliseconds and leaving behind solid particles of the ASD.

The speed of solvent evaporation is what creates the amorphous state. The molecules do not have time to organise into a crystal lattice before the solvent is gone, so they are locked in a disordered, amorphous arrangement within the polymer matrix. The quality of that arrangement, specifically the degree of molecular dispersion of the drug within the polymer, depends on the polymer, the drug loading, and the processing conditions.

Key Process Parameters and Their Effects

Process Parameter	Effect on Spray-Dried Dispersion	Typical Optimisation Approach
Inlet temperature	Drives solvent evaporation rate; affects particle temperature and morphology	Optimise to achieve residual solvent below ICH Q3C limits without thermal degradation of API
Feed concentration	Higher concentration increases throughput; affects particle size and morphology	Balance between yield, particle size target, and solution viscosity
Atomisation rate and type	Controls droplet size and therefore particle size of the SDD	Nozzle type and pressure optimised for target particle size distribution
Outlet temperature	Indicates drying efficiency; must be above glass transition temperature of wet cake	Typically 10-15 degrees C above Tg of formulation; controlled by inlet temperature and feed rate
Nitrogen flow rate	Affects residence time in drying chamber; closed loop systems recover solvent	Matched to feed rate for consistent outlet temperature
Secondary drying	Removes residual solvent to below specification limits	Fluid bed drying or tray drying post-spray; temperature and time optimised by residual solvent measurement

Polymer Selection for Spray-Dried ASDs

The choice of polymer is the single most important formulation decision for a spray-dried ASD. The polymer must be miscible with the drug in the amorphous state, must dissolve in a common solvent with the drug, must form a rigid matrix with a sufficiently high Tg to prevent recrystallisation under storage conditions, and must release the drug appropriately when the dosage form contacts gastrointestinal fluid.

HPMC-AS (hypromellose acetate succinate) is the most widely used polymer for spray-dried ASDs in commercial products, offering good drug stabilisation, pH-dependent dissolution (releasing the drug in the upper small intestine at pH above approximately 5.5), and a well-established regulatory track record. PVPVA (polyvinylpyrrolidone-vinyl acetate) offers faster dissolution and is used where rapid drug release is needed. PVP-K grades and Eudragit systems are also used depending on the molecule and the target release profile.

From Spray Drying to Final Dosage Form

The spray-dried intermediate (the SDD powder) must be converted into a tablet or capsule for clinical and commercial use. The SDD typically has poor flow properties and low bulk density, which can make direct compression challenging. Granulation, either wet granulation or roller compaction, is often required to improve the powder properties before tabletting. The downstream processing step must preserve the particle size of the SDD and avoid conditions that would cause recrystallisation of the amorphous drug.

Ardena’s Spray Drying Capabilities

Ardena operates spray drying capability at its Somerset, New Jersey facility and at Pamplona (Idifarma) in Spain. Both sites provide spray drying for ASD development and GMP clinical manufacturing, with solvent handling systems, closed-loop nitrogen operation, and secondary drying capability. The formulation teams at these sites have developed spray-dried dispersions across a broad range of BCS Class II molecules and polymer systems.

Small Molecule PK Testing: From First Dose to Steady State

The Role of PK Data in Early Clinical Development

Pharmacokinetic data is the foundation on which dose selection decisions are built in early clinical development. Before the first human dose is administered, the preclinical PK profile provides predictions of human exposure based on allometric scaling or physiologically based pharmacokinetic (PBPK) modelling. After the first dose in humans, that prediction is tested against reality, and the clinical PK data that emerges drives every subsequent dosing decision.

For a single ascending dose (SAD) study, PK data from each cohort determines whether escalation to the next dose level is appropriate. For a multiple ascending dose (MAD) study, trough concentrations at steady state confirm whether the dosing interval produces adequate drug exposure between doses. For a food effect study, the comparison of AUC and Cmax in fed and fasted states informs whether the drug needs to be taken with or without food. In each case, the quality of the bioanalytical data directly limits the quality of the clinical decision.

Building the Analytical Method for a New Molecule

Selectivity and Matrix Selection

The first task in developing a bioanalytical method for a new small molecule is establishing selectivity: can the method measure the drug accurately in the presence of the endogenous components of the biological matrix? For most plasma or serum methods, selectivity is demonstrated by showing that the analyte signal in drug-free matrix samples from at least six individual donors is within 20% of the lower limit of quantification (LLOQ), confirming that matrix components do not produce a false signal at the analyte’s retention time and mass transition.

Sensitivity and LLOQ

The LLOQ defines the lowest concentration that can be measured with acceptable precision and accuracy, typically defined as a coefficient of variation below 20% and a bias within plus or minus 20% of the nominal value. Setting the LLOQ appropriately requires an estimate of the lowest plasma concentration expected in the clinical study, which for a SAD study is typically the Cmax at the lowest dose level adjusted for the expected elimination over the last sampling timepoint. For molecules with very long half-lives or very wide dose ranges, the LLOQ requirement may span several orders of magnitude.

Metabolite Coverage

For many small molecules, metabolites are present in plasma at concentrations that can be clinically significant, either because the metabolite is pharmacologically active or because it is associated with toxicity. Regulatory guidance, including the FDA’s 2020 guidance on safety testing of drug metabolites, requires that metabolites present at greater than 10% of parent drug exposure are characterised and assessed for safety. The bioanalytical method must be capable of measuring the relevant metabolites in addition to the parent compound if their concentrations are expected to be clinically relevant.

LC-MS/MS: The Gold Standard for Small Molecule PK

Liquid chromatography tandem mass spectrometry (LC-MS/MS) is the primary analytical platform for quantitative small molecule bioanalysis in regulatory studies. The combination of chromatographic separation with mass selective detection provides the specificity needed to measure a drug and its metabolites at nanomolar or sub-nanomolar concentrations in complex biological matrices, with precision and accuracy that consistently meets ICH M10 acceptance criteria across a wide range of analytes.

Key method development parameters for an LC-MS/MS assay include the choice of ionisation mode (positive or negative electrospray ionisation based on the molecule’s ionisable groups), the chromatographic conditions (stationary phase, mobile phase composition, gradient profile), the mass transitions monitored (typically the precursor ion to at least two fragment ions for confirmation of identity), and the sample preparation approach (protein precipitation, liquid-liquid extraction, or solid-phase extraction based on the required sensitivity and selectivity).

From Single Dose to Steady State: What the PK Data Tells You

PK Study Phase	Key Measurements	Clinical Decision Supported
Single ascending dose (SAD)	Cmax, AUC0-t, AUC0-inf, t1/2, Tmax at each dose level	Dose proportionality; human half-life; dose selection for MAD study
Multiple ascending dose (MAD)	Cmin (trough) at steady state; AUCss; accumulation ratio	Dosing interval confirmation; time to steady state; accumulation characterisation
Food effect study	AUC and Cmax in fed vs fasted state; 90% CI for the ratio	Fasting or fed administration instruction; effect of food on variability
Special population PK	Clearance and exposure in renally or hepatically impaired subjects	Dose adjustment recommendations for labelling
Drug-drug interaction studies	PK of victim drug with and without perpetrator	Labelling of clinically relevant DDIs; dose adjustment requirements

Sample Management and Chain of Custody

The quality of bioanalytical data depends not only on the analytical method but on the handling of the samples from the moment of collection to the moment of analysis. Blood must be collected into the correct anticoagulant tube, processed to plasma or serum within the validated time window, aliquoted correctly, and stored at the validated temperature. Deviations from the validated sample handling procedure can result in analyte degradation that produces systematically low concentrations, invalidating the data.

Ardena’s clinical team at Assen provides sample management services that coordinate sample receipt from clinical sites, log chain of custody, and confirm that sample handling conditions were within validated parameters before analysis proceeds. Samples that have experienced documented excursions are flagged for scientific review before inclusion in the dataset.

Ardena’s Small Molecule PK Bioanalysis at Assen

Ardena’s bioanalytical laboratory in Assen provides fully validated LC-MS/MS methods for small molecule PK studies from early non-clinical through to Phase III. The laboratory operates under GLP and GCP conditions for regulated studies, with ICH M10 compliant validation packages and ISR programmes as standard. The team has experience with plasma, serum, urine, cerebrospinal fluid, and tissue matrices across a wide range of therapeutic areas.

ICH M10 Compliance: What the Bioanalytical Guideline Means in Practice

The Guideline That Harmonised Global Bioanalysis

Before ICH M10, bioanalytical method validation was governed by separate guidance documents from the FDA and EMA that, while broadly aligned, differed in specific requirements for acceptance criteria, validation parameters, and reporting expectations. A study submitted to both agencies might require two slightly different validation packages, creating additional work and potential for inconsistencies. The ICH M10 guideline on bioanalytical method validation and study sample analysis, finalised in 2022, replaced both sets of guidance with a single harmonised global standard that applies to all major regulatory markets.

ICH M10 covers the validation requirements for chromatographic assays (LC-MS/MS, LC-UV, and related methods) and ligand-binding assays (LBAs including ELISA and ECL platforms) used in regulated bioanalysis for pharmacokinetic, toxicokinetic, and biomarker studies. Its adoption has significant practical implications for bioanalytical CROs and for the sponsors who commission regulated studies.

Key Changes and Clarifications Introduced by ICH M10

Topic	Pre-ICH M10 Position	ICH M10 Position
Incurred sample reanalysis (ISR)	Required by FDA and EMA guidance; acceptance criteria broadly similar	Harmonised: 2/3 of reanalysed samples must agree within 20% (chromatographic) or 30% (LBA) of original result
Parallelism for LBAs	Required by EMA; FDA less prescriptive	Required for all regulated LBAs; failure may indicate matrix effects or non-specific binding
Selectivity testing	Test in minimum 6 individual lots of matrix	Minimum 6 lots confirmed; haemolysed and lipaemic matrix testing explicitly addressed
Carryover	Addressed in FDA guidance; less explicit in EMA	Explicit requirement: must demonstrate carryover does not affect accuracy; defined acceptance criteria
Stability of calibration standards	Covered in guidance; variation in specifics	Detailed stability requirements for stock solutions, working solutions, and matrix-based calibrators and QCs
Regulated biomarker assays	Fit-for-purpose concept; less detailed requirements	Separate section on biomarker assays; partial validation acceptable with documented scientific justification
Reference standard characterisation	Required; specifics varied	Explicit requirements for characterisation certificate; purity correction of nominal concentrations

Parallelism: The LBA Requirement That Catches Teams Out

Parallelism is one of the ICH M10 requirements that most frequently requires additional work for teams transitioning from the previous FDA and EMA guidance. Parallelism testing demonstrates that the dose-response curve generated by serially diluting a study sample is parallel to the calibration curve generated from spiked matrix. Non-parallelism indicates that the analyte in study samples is behaving differently from the reference standard used to construct the calibration curve, which may be due to endogenous matrix components interfering with the assay, a different molecular form of the analyte in study samples, or binding of the analyte to carrier proteins.

Parallelism must be demonstrated during method validation using samples from the target population, not just from healthy volunteers, unless the sponsor can provide a scientific justification for why the two populations would not differ. For oncology programmes where the patient population may have elevated levels of endogenous proteins or circulating drug-related metabolites, this requirement can be practically challenging to meet before the first clinical study provides patient samples.

Reference Standard Characterisation and Purity Correction

ICH M10 introduces an explicit requirement to characterise the reference standard used in a validated bioanalytical method and to apply purity correction to the nominal concentrations of calibration standards and quality control samples. This means that if a reference standard is certified at 95% purity, the nominal concentration of a 1 nanogram per millilitre standard should be reported and calculated as 0.95 nanograms per millilitre. This sounds straightforward but has practical implications for the labelling of calibration standards in the laboratory information management system (LIMS) and for the retrospective recalculation of data from studies conducted before purity correction was applied.

Fit-for-Purpose Biomarker Assays Under ICH M10

ICH M10 formally recognises the fit-for-purpose (FFP) validation framework for biomarker assays, providing a tiered structure where the scope of validation experiments is calibrated to the intended use of the data. A biomarker assay used for exploratory characterisation in a Phase I study requires a less comprehensive validation package than the same assay used as a primary efficacy endpoint in a pivotal Phase III trial.

The ICH M10 framework requires that the validation scope for each biomarker assay is justified by the sponsor, with reference to the intended use, the decision-making consequences of the data, and the regulatory context. This justification must be documented and available for regulatory review. The table in the ICH M10 guideline that maps validation parameters to assay categories provides a practical reference for determining which experiments are required for each application.

Ardena’s ICH M10 Compliant Bioanalysis Services

Ardena’s bioanalytical laboratory in Assen operates under ICH M10-compliant method validation procedures for both chromatographic and ligand-binding assays. The standard operating procedures, validation templates, and reporting formats at the Assen facility have been updated to align with the harmonised requirements, and the scientific team is experienced in applying the parallelism, ISR, and reference standard characterisation requirements to both small molecule PK and large molecule LBA programmes.

Aseptic Fill-Finish for Nanomedicines: Preventing Particle Loss

Why Nanoparticle Fill-Finish Is Different

Aseptic fill-finish for a conventional small molecule injectable involves filling a solution into vials under Grade A conditions and sealing them. The process is technically demanding from a contamination control perspective, but the drug product itself is chemically robust enough to withstand the shear forces, surface contacts, and process-related stresses involved without significant changes to its physicochemical properties.

Nanoparticle drug products, including LNPs, liposomes, and polymeric nanoparticles, are far more sensitive to process-related stress. The particles are nano-scale assemblies held together by relatively weak non-covalent interactions, and they can be disrupted by shear forces during pumping and filling, by adsorption to surfaces in the filling equipment and vial, by temperature fluctuations, and by changes in the ionic strength or pH of the vehicle. Any of these events can lead to aggregation, particle size increase, loss of encapsulation efficiency, or active pharmaceutical ingredient loss to surfaces, all of which compromise the quality and clinical performance of the product.

Particle Loss to Surfaces: The Adsorption Problem

One of the most insidious sources of nanoparticle loss during fill-finish is adsorption of particles or their payload to the surfaces of the filling equipment and the vial itself. Lipid nanoparticles, in particular, are prone to adsorbing to hydrophobic surfaces including the tubing used in peristaltic filling pumps, the silicone gaskets in filling needles, and the inner surface of glass vials. mRNA LNPs have been shown to lose a significant fraction of their payload to glass and silicone surfaces under some conditions, reducing the delivered dose below the intended level.

Mitigation strategies include the use of siliconised or coated vials to reduce surface adsorption, the selection of filling equipment materials that are compatible with the specific nanoparticle formulation, and the use of carrier proteins or surfactants in the formulation that preferentially adsorb to surfaces and reduce nanoparticle-surface contact. The extent of surface adsorption must be assessed during process development by measuring drug content in the first and last vials filled in a batch and comparing to the bulk solution.

Shear-Induced Aggregation During Pumping and Filling

Peristaltic pumps and other filling mechanisms subject the drug product to shear forces as it passes through the tubing, pump head, and filling needle. Conventional small molecule solutions are unaffected by these shear forces, but nanoparticle dispersions can aggregate when exposed to sufficiently high shear, particularly at the outlet of the filling needle where flow velocities are highest. Aggregation during filling increases particle size, broadens the PDI, and can eventually produce visible particles that would cause a batch failure.

The shear sensitivity of a specific nanoparticle formulation must be evaluated during process development by measuring particle size and PDI before and after exposure to the filling conditions. Where shear sensitivity is identified, peristaltic pump settings (tube diameter, pump speed, fill volume) must be optimised to keep shear forces below the threshold for aggregation, and the filling process parameters must be included in the validated process description.

Fill-Finish Process Parameters Critical for Nanomedicines

Process Parameter	Risk to Nanoparticle Product	Control Strategy
Pump type and speed	Shear-induced aggregation; particle size increase	Evaluate peristaltic, piston, and time-pressure pumps; optimise speed to minimise shear without sacrificing fill accuracy
Tubing and wetted surface materials	API adsorption; particle disruption at interfaces	Qualify tubing materials for compatibility with specific formulation; use low-adsorption tubing where available
Fill temperature	Particle instability if temperature deviates from formulation optimum	Maintain product temperature during filling; temperature log in filling suite
Fill volume accuracy	Incorrect dose delivered; overfill required to compensate for surface losses	Account for surface adsorption losses in fill volume calculation; validate overfill requirement
Headspace gas	Oxidation of lipid components if air contact occurs	Nitrogen purge of vial headspace before stoppering for lipid-sensitive products
Vial treatment	Enhanced adsorption to untreated glass	Evaluate siliconised, PTFE-lined, or alternative-coated vials for high-adsorption formulations

Analytical Monitoring During Nanoparticle Fill-Finish

In-process monitoring during nanomedicine fill-finish goes beyond the standard fill weight checks used for conventional injectables. Particle size and PDI should be measured on samples taken at the beginning, middle, and end of the fill to detect any process-related changes. Encapsulation efficiency should be confirmed on released product. For mRNA LNP products, mRNA integrity by gel electrophoresis and potency by in vitro translation assay are additional release tests that confirm the product has not been damaged during the fill-finish process.

Ardena’s Nanomedicine Fill-Finish Expertise at Ghent

Ardena’s sterile manufacturing team in Ghent has specific experience with the fill-finish requirements of nanomedicine products, including LNPs and liposomal formulations. Process development for nanoparticle fill-finish at Ardena includes surface adsorption assessment, shear sensitivity testing, and in-process particle size monitoring to ensure that the filled product meets its CQA specifications.

Complex Injectable Formulations: Suspensions, Emulsions, and Liposomes

Beyond the Simple Solution

The simplest injectable drug product is a solution: the API is fully dissolved in a compatible aqueous vehicle, the solution is sterile filtered, and it is filled into vials or prefilled syringes. A significant proportion of the injectable pipeline, however, cannot be formulated as simple solutions. Poorly water-soluble APIs, APIs that are unstable in solution, molecules that need to be targeted to specific tissues, and biologics that require depot-forming formulations for sustained release all require more complex formulation architectures.

Suspensions, emulsions, and liposomal systems are the three most clinically established complex injectable formulation platforms. Each offers distinct advantages for the right molecule, and each brings formulation challenges and manufacturing complexity that require specialist expertise to navigate.

Pharmaceutical Suspensions for Injection

A parenteral suspension consists of solid drug particles dispersed in an aqueous vehicle. Suspensions are used when the API has poor aqueous solubility, when a depot effect is desired (slowly dissolving drug particles at the injection site providing sustained release), or when the drug is more stable in solid form than in solution.

The critical quality attributes for injectable suspensions include particle size distribution (which affects both syringeability and dissolution rate at the injection site), resuspendability (the ability to achieve a uniform dispersion after settling with minimal shaking), viscosity (which must be low enough to allow injection through the intended needle gauge), and physical and chemical stability over shelf life.

Particle size control in injectable suspensions requires either micronisation of the API before suspension, or controlled crystallisation in the suspension medium. The final suspension must be sterilised, which for crystalline suspensions rules out sterile filtration and typically requires either terminal sterilisation (if the product is stable to autoclaving) or aseptic processing of each component followed by aseptic blending. ICH Q6A provides the quality standards framework for suspension characterisation.

Pharmaceutical Emulsions for Injection

Injectable emulsions are thermodynamically unstable two-phase systems in which one liquid is dispersed as droplets within another immiscible liquid, stabilised by an emulsifier. For pharmaceutical applications, oil-in-water (O/W) emulsions are most common, used to solubilise lipophilic APIs in the oil phase and deliver them via intravenous or intramuscular injection. Propofol, the widely used anaesthetic, is the most familiar example of an injectable O/W emulsion.

The critical attributes of injectable emulsions include droplet size (typically below 500 nanometres for intravenous emulsions, to prevent embolism risk), zeta potential (which governs colloidal stability), and drug distribution between the oil and aqueous phases (which affects dose uniformity). Physical stability, particularly resistance to droplet coalescence and Ostwald ripening over the product shelf life, is the primary formulation challenge and is addressed through emulsifier selection, oil phase composition, and processing conditions.

Liposomal Drug Products

Liposomes are spherical vesicles formed from phospholipid bilayers that enclose an aqueous core. The bilayer structure allows hydrophilic drugs to be encapsulated in the aqueous interior and lipophilic drugs to be incorporated into the bilayer membrane, making liposomes versatile carriers for a wide range of APIs. Commercially approved liposomal products include liposomal doxorubicin (Doxil/Caelyx), liposomal amphotericin B (AmBisome), and the COVID-19 mRNA vaccine lipid nanoparticles, which are closely related to classical liposomes.

Formulation Type	API Suitability	Key Stability Challenges	Primary Clinical Advantage
Injectable suspension	Poorly water-soluble crystalline APIs; sustained release depot	Particle size growth; physical instability; syringeability	Sustained release at injection site; suitable for low-solubility compounds
Injectable emulsion	Lipophilic APIs requiring IV or IM delivery; propofol-like molecules	Droplet coalescence; Ostwald ripening; API leakage from oil phase	Solubilisation of lipophilic APIs; IV administration possible
Conventional liposome	Hydrophilic APIs (aqueous core) or lipophilic APIs (bilayer)	Aggregation; drug leakage; phospholipid oxidation and hydrolysis	Extended circulation time; reduced systemic toxicity vs free drug
PEGylated liposome	As above; particularly cytotoxic oncology agents	As above; PEG shedding over time	Stealth effect; avoids rapid clearance by mononuclear phagocyte system
Targeted liposome	APIs requiring cell-specific delivery; ADC-like specificity	As above; ligand stability; targeting efficiency in vivo	Active targeting to tumour or specific cell type; improved therapeutic index

Manufacturing Considerations for Complex Injectables

Each of the formulation types described above requires a different manufacturing approach, and all share the requirement for aseptic processing to produce a sterile final product. Liposomal products are typically manufactured by thin-film hydration or microfluidics-based approaches, with size reduction by extrusion or high-pressure homogenisation and remote loading of the API after vesicle formation for ionisable drugs. Injectable emulsions are prepared by high-shear homogenisation followed by high-pressure homogenisation to achieve the target droplet size.

For all three formulation types, sterilisation is a particular challenge. The physical structures involved (crystals, droplets, vesicles) cannot withstand terminal steam sterilisation, so aseptic manufacturing, with the stringent environmental controls and validated processes that entails, is the standard approach.

Ardena’s Complex Injectable Capabilities at Ghent

Ardena’s development and manufacturing team in Ghent has formulation and manufacturing experience across injectable suspensions, emulsions, and liposomal products. The facility’s aseptic fill-finish capability supports GMP manufacturing of these complex dosage forms for clinical supply, with analytical support for the particle size, drug content, and stability testing required for regulatory filings.

Lyophilisation Cycle Development: A Guide for Biologics

Why Biologics Need Lyophilisation

Proteins, monoclonal antibodies, enzymes, and other biological molecules are inherently unstable in aqueous solution. In solution, they are subject to hydrolysis, oxidation, deamidation, aggregation, and physical denaturation, degradation pathways that can reduce potency, alter immunogenicity, and compromise the safety of the product. For biologics with an intended shelf life of two years or more, maintaining adequate chemical and physical stability in a liquid formulation is often not feasible without cold chain storage that is impractical for global distribution.

Lyophilisation, or freeze-drying, addresses this by removing water from the formulation while maintaining the structural integrity of the biologic molecule, converting the liquid drug product into a stable solid cake that can be stored at ambient or refrigerated temperature and reconstituted immediately before use. The process is technically demanding, time-consuming, and equipment-intensive, but for many biologics it is the only route to a commercially viable product.

The Three Phases of a Lyophilisation Cycle

Freezing

In the freezing phase, the liquid drug product in the vials is cooled to a temperature below the eutectic point or glass transition temperature of the formulation. The rate of freezing is critical. Slow freezing produces large ice crystals that create a coarser cake structure with good mass transfer properties during drying. Rapid freezing produces small ice crystals and a denser cake structure. Controlled nucleation, the induction of ice crystal formation at a defined temperature, is an emerging technique for improving freeze-drying cycle consistency and reducing vial-to-vial variability in cake structure.

Primary Drying

In primary drying, the chamber pressure is reduced and the shelf temperature is raised to supply the heat of sublimation, driving water directly from the frozen ice phase to vapour without passing through a liquid phase. The product temperature during primary drying must remain below the collapse temperature, which is typically close to the glass transition temperature of the maximally freeze-concentrated solution (Tg prime). Collapse, the loss of the porous cake structure, results in a product with reduced reconstitution performance and potentially altered potency.

Secondary Drying

After all ice has been sublimed, secondary drying removes the residual bound water from the amorphous matrix by desorption. The shelf temperature is raised to typically 20 to 40 degrees Celsius and held for several hours. The target residual moisture content for most lyophilised biologics is below 1%, as residual water acts as a plasticiser that reduces the Tg of the dried cake and increases molecular mobility, accelerating degradation.

Critical Formulation Components for Lyophilisation

Excipient Role	Common Examples	Function in the Lyophilisate
Bulking agent	Mannitol, glycine, sucrose	Provides physical structure to the cake; prevents collapse of the matrix during drying
Cryoprotectant	Sucrose, trehalose, sorbitol	Protects the protein during freezing by replacing water in the protein hydration shell; reduces denaturation
Lyoprotectant	Sucrose, trehalose	Protects the protein during drying; glass-forming excipients that immobilise the protein in a rigid amorphous matrix
Buffer	Histidine, citrate, phosphate	Maintains pH during reconstitution; some buffers crystallise during freezing and can cause pH shift; histidine preferred for many biologics
Surfactant	Polysorbate 20 or 80, poloxamer 188	Prevents protein aggregation at interfaces during freezing, drying, and reconstitution
Tonicity modifier	NaCl, mannitol, sucrose	Ensures reconstituted product is isotonic for injection

Cycle Development and Scale-Up Considerations

Lyophilisation cycle development begins at laboratory scale using a small-scale freeze-dryer with full data logging capability. The critical parameters to establish are the collapse temperature or Tg prime of the formulation, the primary drying shelf temperature and chamber pressure that keep the product below collapse temperature while maximising sublimation rate, and the secondary drying conditions that achieve the target residual moisture.

Scale-up from laboratory to GMP manufacturing scale is not straightforward. Heat and mass transfer characteristics differ between dryers of different sizes and designs, and the cycle parameters optimised at lab scale rarely transfer directly to a larger dryer without modification. Computational modelling approaches and process analytical technology including temperature probes (thermocouples), pressure rise testing, and near-infrared spectroscopy for real-time endpoint detection are increasingly used to facilitate scale-up and cycle transfer between facilities.

Ardena’s Lyophilisation Capabilities at Ghent

Ardena’s sterile manufacturing facility in Ghent operates lyophilisation capacity for both development and GMP clinical batch manufacture. The lyophilisation team has experience with small molecule, peptide, and biologic lyophilised products, and can support cycle development from initial formulation characterisation through to GMP-validated cycle execution.